trial · primary record
Tiragolumab
Solid Tumor, Adult
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 96 |
| Primary completion | 2028-03-01 |
| Primary endpoint | Progression Free Survival (PFS) rate at 6 Months |
| Registry ID | NCT06003621 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:35:13.157Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06003621
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.